RESEARCH TRIANGLE PARK, NC--(Marketwire - June 24, 2008) - Compliance departments at pharmaceutical companies have had to be even more stringent in their governance of the way they handle their off-label discussions since the introduction of the Office of the Inspector General’s (OIG) guidelines, according to a new report by Cutting Edge Information. The study, “Monitoring and Ensuring Pharmaceutical Compliance,” reveals that the guidelines, which came out in 2003, have had a significant impact on company practices at 75% of the companies surveyed.
